Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Sarah Aebersold, the Chief Human Resources Officer at BioLife Solutions Inc. (NASDAQ:BLFS), recently sold a portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Aebersold sold 210 shares of BioLife Solutions’ common stock on April 9, 2025. The shares were sold at an average price of $20.11 each, amounting to a total transaction value of $4,223. The transaction comes as BioLife Solutions, with a market capitalization of $1.03 billion, has shown strong performance with a 28% gain over the past year despite recent volatility. InvestingPro analysis indicates the stock is trading above its Fair Value.
Following this sale, Aebersold holds 79,884 shares of BioLife Solutions. The company maintains a healthy financial position with a current ratio of 4.54, indicating strong liquidity. The transaction was conducted under a Rule 10b5-1 trading plan, which was adopted to satisfy tax withholding obligations related to the vesting of restricted stock. For deeper insights into BLFS’s financial health and additional ProTips, visit InvestingPro, where you’ll find comprehensive analysis and expert research reports.
In other recent news, BioLife Solutions reported strong financial results for the fourth quarter of 2024, with revenue reaching $22.7 million, surpassing analyst estimates of $21.3 million. The company also posted a net loss of $2.0 million, which was smaller than the projected loss of $4.4 million. BioLife’s Cell Processing segment saw a 31% year-over-year increase in revenue, marking the fifth consecutive quarter of growth for this segment. Looking forward, BioLife anticipates 2025 revenue to range between $95.5 million and $99 million, reflecting a 16-20% increase over 2024.
Analysts have responded positively to these developments, with KeyBanc maintaining an Overweight rating and a $33 price target, while H.C. Wainwright raised its price target to $30 from $27, maintaining a Buy rating. Benchmark also reiterated a Buy rating with a $30 target following the company’s strong performance. BioLife’s biopreservation media is now incorporated into 17 approved cell and gene therapies, with expectations for additional approvals or expansions in the coming year. The company has also completed the sale of a non-core product line to focus on improving gross margins and adjusted EBITDA margins. BioLife’s management projects Cell Processing revenue to grow 18-21% in 2025, demonstrating confidence in the company’s continued financial health and operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.